Form 4: Intra-Cellular Therapies EVP and General Counsel Michael Halstead Reports Stock Sales
SEC Form 4
Michael Halstead, EVP and General Counsel of Intra-Cellular Therapies, Inc., reports the sale of common stock and vesting of restricted stock units.
Summary
- On March 7, 2024, Michael Halstead sold 12,912 shares of Intra-Cellular Therapies common stock at a weighted average price of $66.14 and 220 shares at a weighted average price of $66.81.
- On March 10, 2024, 7,345 restricted stock units vested and converted into common stock.
- On March 11, 2024, Halstead sold 6,107 shares at a weighted average price of $65.82 and 1,238 shares at a weighted average price of $66.70.
- The sales were executed under a Rule 10b5-1 trading plan adopted on March 15, 2023, and amended on May 8, 2023, and August 11, 2023.
- A majority of the proceeds from the sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock sales by an executive under a pre-existing trading plan. It doesn't inherently indicate positive or negative news about the company.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for executives who receive stock-based compensation. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on current market information.
Key Dates
| Date | Description |
|---|---|
| 2022-03-10 | Reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |
| 2023-03-15 | Original adoption date of Rule 10b5-1 trading plan. |
| 2023-05-08 | Amendment date of Rule 10b5-1 trading plan. |
| 2023-08-11 | Amendment date of Rule 10b5-1 trading plan. |
| 2024-03-07 | Sale of common stock. |
| 2024-03-10 | Restricted stock units vested. |
| 2024-03-11 | Sale of common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.